PatientWing

No information available

Showing 1 - 10of11studies

Myelodysplastic Syndromes Clinical Trial

Featured Trial

Myelodysplastic Syndromes Clinical Trial
NCT02841540 - Phase 1 - Interventional

The goal of this study is to evaluate whether the investigational drug will help patients with lower-risk MDS improve their symptoms and reduce their number of transfusions.

Recruiting

Male & Female

18 Years +


Primary Sclerosing Cholangitis Clinical Trial

Featured Trial

Primary Sclerosing Cholangitis Clinical Trial
NCT04595825 - Phase 2 - Interventional

This study is designed to assess the safety, tolerability and activity of CM-101 in patients with Primary Sclerosing Cholangitis (PSC).

Recruiting

Male & Female

18 - 75

Years old


Higher-Risk MDS Study

Featured Trial

Higher-Risk MDS Study
NCT05428969 - Phase 1 phase 2 - Interventional

Higher-Risk MDS Study

Recruiting

Male & Female

18 Years +


Focal Onset Seizures Clinical Trial

Featured Trial

Focal Onset Seizures Clinical Trial
NCT05614063 - Phase 3 - Interventional

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

Recruiting

Male & Female

18 Years +


IgG4-RD Clinical Trial

Featured Trial

IgG4-RD Clinical Trial
PWT12142022 - Phase 3 - Interventional

The purpose of this study is to learn if a new investigational medicine called obexelimab can safely help prevent flares associated with IgG4-related disease.

Recruiting

Male & Female

18 Milliseconds +


Primary Generalized Tonic-Clonic Seizures Clinical Trial

Featured Trial

Primary Generalized Tonic-Clonic Seizures Clinical Trial
NCT05667142 - Phase 3 - Interventional

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Recruiting

Male & Female

18 Years +


Warm Autoimmune Hemolytic Anemia Clinical Trial

Featured Trial

Warm Autoimmune Hemolytic Anemia Clinical Trial
NCT05786573 - Phase 3 - Interventional

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Recruiting

Male & Female

18 Years +


PW TEST FOS

Featured Trial

PW TEST FOS
PWTID0817202301 - Phase 2 phase 3 - NA

FOS Test

Recruiting

Female

All ages


PW TEST PGTCS

Featured Trial

PW TEST PGTCS
PWTID0817202302 - Phase 2 phase 3 - NA

PGTCS Test

Recruiting

Female

All ages


HZN-1116-201

Featured Trial

HZN-1116-201
PWT11152023 - Phase 2 - Interventional

HZN-1116-201

Recruiting

Male & Female

18 - 75

Milliseconds old


Connect with Us

No information available

Info

No information available

No information available

No web site available